Literature DB >> 10926284

Erythropoietin therapy for premature infants: cost without benefit?

A Zipursky.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10926284     DOI: 10.1203/00006450-200008000-00002

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


× No keyword cloud information.
  7 in total

Review 1.  Neonatal transfusion practice.

Authors:  N A Murray; I A G Roberts
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2004-03       Impact factor: 5.747

Review 2.  Early erythropoiesis-stimulating agents in preterm or low birth weight infants.

Authors:  Arne Ohlsson; Sanjay M Aher
Journal:  Cochrane Database Syst Rev       Date:  2017-11-16

3.  Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants.

Authors:  Sanjay M Aher; Arne Ohlsson
Journal:  Cochrane Database Syst Rev       Date:  2020-02-11

4.  High Prevalence of Iron Deficiency Despite Standardized High-Dose Iron Supplementation During Recombinant Erythropoietin Therapy in Extremely Low Gestational Age Newborns.

Authors:  Ashajyothi M Siddappa; Rose M Olson; Miriam Spector; Elise Northrop; Tara Zamora; Ann M Brearley; Michael K Georgieff; Raghavendra Rao
Journal:  J Pediatr       Date:  2020-05-14       Impact factor: 4.406

5.  Late erythropoiesis-stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants.

Authors:  Sanjay M Aher; Arne Ohlsson
Journal:  Cochrane Database Syst Rev       Date:  2019-02-15

6.  Late erythropoiesis-stimulating agents to prevent red blood cell transfusion in preterm or low birth weight infants.

Authors:  Sanjay M Aher; Arne Ohlsson
Journal:  Cochrane Database Syst Rev       Date:  2020-01-28

7.  Early erythropoiesis-stimulating agents in preterm or low birth weight infants.

Authors:  Arne Ohlsson; Sanjay M Aher
Journal:  Cochrane Database Syst Rev       Date:  2020-02-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.